Colorectal cancer vaccine - Vaccinogen

Drug Profile

Colorectal cancer vaccine - Vaccinogen

Alternative Names: OncoVAX

Latest Information Update: 05 Nov 2015

Price : $50

At a glance

  • Originator Intracel Corporation
  • Developer Intracel Corporation; Vaccinogen
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Colorectal cancer
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Colorectal cancer
  • No development reported Malignant melanoma; Renal cancer
  • Discontinued Ovarian cancer

Most Recent Events

  • 24 Jun 2015 Colorectal cancer vaccine is still in Preregistration for Colorectal cancer (Adjuvant therapy) in Switzerland
  • 14 May 2015 Phase-III clinical trials in Colorectal cancer (Adjuvant therapy) in USA (Intradermal)
  • 26 Aug 2014 Vaccinogen prepares to initiate the phase IIIb ACTIVE trial in Colorectal cancer under a Special Protocol Assessment classification in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top